MVP、CAP和EP方案治疗非小细胞肺癌的疗效比较  

Comparison of MVP and CAP and EP chemotherapy in the management of NSCLC

作　　者：吴江[1] 杨少华[1] 潘达超[2,3] 

机构地区：[1]深圳市宝安人民医院肿瘤科 [2]湛江 524001 [3]广东医学院附属医院肿瘤科

出　　处：《临床肿瘤学杂志》2001年第2期137-139,共3页Chinese Clinical Oncology

摘　　要：目的:探讨和比较MVP、CAP、EP三种不同化疗方案治疗非小细胞肺癌的疗效和毒副作用。方法:104例经病理确诊为非小细胞肺癌患者随机分为3组,分别接受MVP、CAP、EP化疗方案治疗,观察各组的临床疗效、毒副反应并进行x2检验比较。结果:MVP、CAP和EP3个不同化疗方案组的有效率分别是37.1％（13/35）、34.3％（12/35）、20.1％（7/34）,各组间疗效相似（P>0.05）。MVP脱发的发生率和程度较CAP和EP方案低（P<0.05）,年老体弱患者对MVP方案能耐受,未发现心脏毒性。结论:MVP化疗方案可与CAP与EP方案一样作为治疗非小细胞肺癌的临床一线方案应用。Purpose: To evaluate and compare the responses and toxicities in treatment of NSCLC patients with different chemotherapy regimen, MVP, CAP and EP. Methods; 104 patients with NSCLC were randomly divided into three groups, they received MVP(35 cases), CAP(35 cases), EP(34 cases) chemotherapy respectively, the responses and toxicities were observed and compared by x2 test among them.Results: The response rates of the three groups (MVP, CAP, EP regimen) were 37.1 % (13/35), 34.3% (12/35) and 20.4% (7/34) respectively(P>0.05), the toxic reactions were tolerable in three groups.Conclusion:MVP regimen can be recommened as the first choice in treatment of NSCLC as well as CAP or EP regimen.

关 键 词：非小细胞肺肿瘤 长春花碱酰胺 顺铂 丝裂霉素 MVP方案 CAP方案 EP方案 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]